How do women experience a change in their clinically-derived breast cancer risk estimates: views from a UK family history risk and prevention clinic.
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.
Anti-progestin therapy targets hallmarks of breast cancer risk.
Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer.
Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy.
Illness risk representations underlying women's breast cancer risk appraisals: A theory-informed qualitative analysis.
Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer
Mammographic density assessed using deep learning in women at high risk of developing breast cancer: the effect of weight change on density.
The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme
2025cited by 0position: contributor
The feasibility of risk-stratified screening as routine practice in the NHS Breast Screening Programme in England: the PROCAS2 research programme
A randomised controlled trial of short-term Intermittent Energy Restriction [IER] versus Continuous Energy Restriction [CER] on body fat stores and measures of insulin resistance in women with obesity at increased risk of breast cancer.
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.
Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction
Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset
Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.
Germline testing of <i>BRCA1</i>, <i>BRCA2</i>, <i>PALB2</i> and <i>CHEK2</i> c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of <i>ATM</i>, <i>RAD51C</i> and <i>RAD51D</i> in over 400.
Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond <i>BRCA2, BRCA1</i> and <i>CHEK2</i>.
Are Women's Breast Cancer Risk Appraisals in Line with Updated Clinical Risk Estimates Communicated? Results from a UK Family History Risk and Prevention Clinic.
Population-based germline testing of <i>BRCA1, BRCA2</i>, and <i>PALB2</i> in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testing.
Long term follow-up of women treated for screen detected atypical ductal hyperplasia or lobular neoplasia in a large UK screening centre.
Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy.
Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?
An app promoting weight gain prevention via healthy behaviours amongst young women with a family history of breast cancer: Acceptability and usability assessment.
Experiences of a Digital Behavior Change Intervention to Prevent Weight Gain and Promote Risk-Reducing Health Behaviors for Women Aged 18 to 35 Years at Increased Risk of Breast Cancer: Qualitative Interview Study.
Data from Are Women’s Breast Cancer Risk Appraisals in Line with Updated Clinical Risk Estimates Communicated? Results from a UK Family History Risk and Prevention Clinic
Supplementary Materials 1 from Are Women’s Breast Cancer Risk Appraisals in Line with Updated Clinical Risk Estimates Communicated? Results from a UK Family History Risk and Prevention Clinic
Experiences of a Digital Behavior Change Intervention to Prevent Weight Gain and Promote Risk-Reducing Health Behaviors for Women Aged 18 to 35 Years at Increased Risk of Breast Cancer: Qualitative Interview Study (Preprint)
Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Genetics · Oncology →